There is limited published information about prognostic factors and the progression of H3 K27M-mutant glioma. Therefore, this natural history study aims to better define the response to treatment, natural disease progression, outcomes, and prognostic factors in patients with H3 K27M-mutant and/or midline glioma. Furthermore, this study will provide contextual data for the ONC201 clinical development program.
A Retrospective Study Observational Study for H3 K27M-nutenat and/or Midline Gliomas
Schedule An Appointment
Coronavirus (COVID-19) Advisory: Please help us limit exposure. Learn more about COVID-19 and where to go if you have concerns.